{"id":52726,"date":"2026-03-31T19:46:09","date_gmt":"2026-03-31T19:46:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/52726\/"},"modified":"2026-03-31T19:46:09","modified_gmt":"2026-03-31T19:46:09","slug":"slash-your-wegovy-costs-novo-nordisk-reveals-first-ever-subscription-plan-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/52726\/","title":{"rendered":"Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan – Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an expansion of its treatment portfolio for adults with obesity<\/a>.<\/p>\n

The newly approved Wegovy HD (semaglutide) injection 7.2 mg is for patients who have already tolerated the currently approved 2.4 mg dose and require additional weight reduction<\/a>.<\/p>\n

Targets Cost Barriers With Subscription Model<\/p>\n

The program<\/a>, available starting March 31, 2026, allows eligible patients to access FDA-approved treatment through select telehealth providers at a fixed monthly cost.<\/p>\n

Wegovy Tiered Pricing Structure Offers Annual Savings<\/p>\n

Novo Nordisk outlined a tiered pricing structure based on subscription duration, with longer commitments offering lower monthly costs.<\/p>\n

For Wegovy injections, monthly pricing ranges from $329 under a three-month plan to $249 under a 12-month plan, translating into annual savings of up to $1,200.<\/p>\n

The oral version is priced between $289 and $249 per month, with potential savings of up to $600 annually.<\/p>\n

Additional lower-dose options are available at reduced rates, with certain promotional pricing set to expire later in 2026.<\/p>\n

The company noted that limited-time offers are separate from subscription pricing and may vary by platform.<\/p>\n

Telehealth Partnerships Drive Wegovy Distribution<\/p>\n

Novo Nordisk said patients should contact providers directly for eligibility and enrollment details, as terms may differ across platforms.<\/p>\n

Wegovy Broader Access And Long-Term Treatment Focus<\/p>\n

The company emphasized that obesity requires ongoing management under medical supervision, positioning the subscription model as a way to encourage treatment continuity.<\/p>\n

Beyond telehealth, Wegovy remains available through more than 70,000 U.S. pharmacies and NovoCare Pharmacy.<\/p>\n

Patients with commercial insurance may access the drug for as little as $25 per month through existing savings programs.<\/p>\n

Last week, at least six Indian pharmaceutical companies introduced generic versions of Novo Nordisk\u2019s Ozempic and Wegovy<\/a>.<\/p>\n

Following the expiration of the Indian patent for semaglutide last week, these manufacturers are offering treatments at globally unmatched prices, effectively reducing costs by approximately 70%.<\/p>\n

NVO Stock Price Activity: Novo Nordisk shares were up 1.45% at $35.80 at the time of publication on Tuesday, according to Benzinga Pro data<\/a>.<\/p>\n

Image via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Earlier in March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of Wegovy, marking an…\n","protected":false},"author":2,"featured_media":43868,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2092,2088,5813,2084,272,352,2095,29179,2096,2099,2100],"class_list":{"0":"post-52726","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-movers","13":"tag-category-news","14":"tag-category-top-stories","15":"tag-cms-wordpress","16":"tag-novo-nordisk","17":"tag-pageisbzpro-bz","18":"tag-symbol-hims","19":"tag-symbol-lfmd","20":"tag-symbol-nvo","21":"tag-tag-weight-loss","22":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116325514309340667","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=52726"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/52726\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/43868"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=52726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=52726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=52726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}